Heparin-induced Thrombocytopenia Clinical Trial
Official title:
Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
The main objective of this work is to assess the intraoperator reproducibility in the calculation of the HEP score in a population of intensive care patients.
The "HEP score" (HIT Expert Probability) is also a clinical probability score, created thanks to the experience of clinicians (16). It is very recent and therefore still little studied and little used. In particular, it has not been the subject of a prospective validation study for ICU patients. The use of this score is therefore not recommended in everyday practice. However, the literature shows a higher diagnostic value of the HEP score especially for resuscitation-type patients, as well as when used by an operator with little experience. This could be due to greater detail given in consideration of other causes of thrombocytopenia (17). The main objective of this work is to assess the intraoperator reproducibility in the calculation of the HEP score in a population of intensive care patients. The secondary objectives will aim to: - Evaluate inter-operator reproducibility - Determine if the reproducibility of the HEP score is influenced by: The patient's sex The type of heparin used (LMWH vs UFH) The severity of the patient (IGS2 score) A history of cardiac or orthopedic surgery The expected consistent benefits allow validation of the HEP score in surgical intensive care (cf. EVHEP-TIH study). This would allow a better assessment of the pre-test probabilities of TIH with the performance of biological tests. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00759083 -
Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients
|
Phase 4 | |
| Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
| Completed |
NCT00456326 -
Heparin-Induced Thrombocytopenia Registry
|
N/A | |
| Terminated |
NCT00673439 -
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
|
Phase 2 | |
| Active, not recruiting |
NCT00198575 -
A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients
|
N/A | |
| Completed |
NCT00283322 -
Heparin Antibodies in Intensive Care Unit Patients (HAICU)
|
N/A | |
| Not yet recruiting |
NCT05586854 -
Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia
|
N/A | |
| Not yet recruiting |
NCT03269019 -
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
|
N/A | |
| Not yet recruiting |
NCT06066762 -
Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
|
||
| Terminated |
NCT03809481 -
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
|
Phase 3 | |
| Completed |
NCT05325346 -
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
|
Phase 1 | |
| Recruiting |
NCT02717039 -
Pharmacogenomics of Heparin-Induced Thrombocytopenia
|
||
| Completed |
NCT02526485 -
Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
|
||
| Completed |
NCT00748839 -
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
|
N/A | |
| Recruiting |
NCT05783895 -
Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
|
||
| Completed |
NCT00198588 -
Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia
|
Phase 3 | |
| Recruiting |
NCT04842760 -
PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
|
||
| Terminated |
NCT01598168 -
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
|
Phase 3 | |
| Completed |
NCT01654848 -
Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients
|
N/A | |
| Withdrawn |
NCT00603824 -
Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
|
Phase 4 |